Ardelyx, Inc. (ARDX)
NasdaqGM · USD · Healthcare · Biotechnology
$3.00 (+0.00%) as of
Key statistics
- Market cap
- 774.56M
- Forward P/E
- 10.33
- EPS (TTM)
- -0.2300
- Dividend yield
- 0.00%
- 52-week range
- 2.9700 – 8.4000
- Beta
- 0.68
- Revenue (TTM)
- 450.89M
- Profit margin
- -12.35%
- Analyst target
- $12.80
- Volume
- 4.86M
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA, United States
- Employees
- 489
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.